Other agents approved for controlling GVHD, such as JAK2 inhibitor (Ruxolitinib), IL-2 receptor antagonist (Basiliximab), can also be considered used against the over-reacted inflammation in the CAR-T therapy22,23. Here, JAK2 is linked to graft versus host disease.